Express Mail No.: <u>EL 451 596 906 US</u>

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Dasseux et al.

Serial No.: to be assigned

Group Art Unit: to be assigned

Filed: herewith

Examiner: to be assigned

For:

APOLIPOPROTEIN A-I AGONISTS

Attorney Docket No.: 9196-019-999 AND THEIR USE TO TREAT

DYSLIPIDEMIC DISORDERS

PRELIMINARY AMENDMENT UNDER 37 C.F.R. §1.115

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

In accordance with Rule 115 of the Rules of Practice, please enter the following amendment prior to examination of the above-captioned application.

AMENDMENT

IN THE CLAIMS

Please cancel Claims 2-15, 19-24, 26-32, 34-39, 41-49 and 51-52 without prejudice.

CONCLUSION

Applicants submit that Claims 1, 16-18, 25, 33, 40 and 50 of the captioned Application satisfy all of the requirements for patentability and are in condition for allowance. Passage of Claims 1, 16-18, 25, 33, 40 and 50 to issuance is therefore kindly solicited.

Respectfully submitted,

Dated: May 25, 2001

42,983

Rahul Pathak

(Reg. No.)

For: Laura A. Coruzzi (Reg. No. 30,742)

PENNIE & EDMONDS LLP 1155 Avenue of the Americas New York, New York 10036-2711

(212) 790-9090